
Sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affects central regulation of appetite and satiety, which results in increased carbohydrate intake. It has now been demonstrated that these effects might be blunted by combining SGLT2 inhibitors with glucagon-like peptide 1 receptor agonists to further facilitate weight loss in patients with type 2 diabetes mellitus.
Like
Save
Share